Advertisement

The role of ustekinumab and vedolizumab in management of extra intestinal manifestations in inflammatory bowel disease

Published:October 29, 2022DOI:https://doi.org/10.1016/j.dld.2022.10.007
      In recent years, the development of ustekinumab and vedolizumab has further improved the treatment of inflammatory bowel disease (IBD), offering additional therapeutic options to achieve induction and maintenance of remission in both ulcerative colitis (UC) and Crohn's disease (CD). However, data about the impact on extra-intestinal manifestations (EIMs) of IBD are limited [
      • Shim HH
      • Chan PW
      • Chuah SW
      • Schwender BJ
      • Kong SC
      • Ling KL.
      A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.
      ]. In this issue, Margolin et al. [
      • Margolin ML
      • Ling D
      • Attia-Konyo S
      • Abitbol CM
      • Haj-Natour O
      • Ungar B
      • et al.
      Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
      ] have reported the effect of ustekinumab and vedolizumab in EIMs of IBD.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Shim HH
        • Chan PW
        • Chuah SW
        • Schwender BJ
        • Kong SC
        • Ling KL.
        A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases.
        JGH Open: Open Access J Gastroenterol Hepatol. 2018; 2: 223-234
        • Margolin ML
        • Ling D
        • Attia-Konyo S
        • Abitbol CM
        • Haj-Natour O
        • Ungar B
        • et al.
        Ustekinumab and vedolizumab for extraintestinal manifestations in inflammatory bowel disease - a retrospective study.
        Dig Liver Dis. 2022;
        • De Galan C
        • Truyens M
        • Peeters H
        • Mesonero Gismero F
        • Elorza A
        • Torres P
        • et al.
        The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study.
        J Crohn's Colitis. 2022;
        • Feagan BG
        • Sandborn WJ
        • Colombel JF
        • Byrne SO
        • Khalid JM
        • Kempf C
        • et al.
        Incidence of arthritis/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: post hoc analyses of the GEMINI trials.
        J Crohn's Colitis. 2019; 13: 50-57
        • Chateau T
        • Bonovas S
        • Le Berre C
        • Mathieu N
        • Danese S
        • Peyrin-Biroulet L
        Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: a systematic review.
        J Crohn's Colitis. 2019; 13: 1569-1577
        • Alivernini S
        • Pugliese D
        • Tolusso B
        • Felice C
        • Gremese E
        • Armuzzi A.
        Comment on: emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease.
        Rheumatology. 2019; 58: 1113-1115
        • Cleynen I
        • Vermeire S.
        Paradoxical inflammation induced by anti-TNF agents in patients with IBD.
        Nat Rev Gastroenterol Hepatol. 2012; 9: 496-503
        • Adams DH
        • Eksteen B.
        Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease.
        Nat Rev Immunol. 2006; 6: 244-251
        • Guillo L
        • D'Amico F
        • Danese S
        • Peyrin-Biroulet L
        Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.
        J Crohn's Colitis. 2021; 15: 1236-1243
        • Guenova E
        • Teske A
        • Fehrenbacher B
        • Hoerber S
        • Adamczyk A
        • Schaller M
        • et al.
        Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab.
        Arch Dermatol. 2011; 147: 1203-1205
        • Chateau T
        • Angioi K
        • Peyrin-Biroulet L.
        Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn's disease.
        J Crohn's Colitis. 2020; 14: 571
        • Pepple KL
        • Lin P.
        Targeting interleukin-23 in the treatment of noninfectious uveitis.
        Ophthalmology. 2018; 125: 1977-1983
        • Biemans VBC
        • van der Meulen-de Jong AE
        • van der Woude CJ
        • Lowenberg M
        • Dijkstra G
        • Oldenburg B
        • et al.
        Ustekinumab for Crohn's disease: results of the ICC registry, a nationwide prospective observational cohort study.
        J Crohn's Colitis. 2020; 14: 33-45
        • Kavanaugh A
        • Ritchlin C
        • Rahman P
        • Puig L
        • Gottlieb AB
        • Li S
        • et al.
        Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.
        Ann Rheum Dis. 2014; 73: 1000-1006
        • Deodhar A
        • Gensler LS
        • Sieper J
        • Clark M
        • Calderon C
        • Wang Y
        • et al.
        Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.
        Arthritis Rheumatol. 2019; 71: 258-270
        • Liefferinckx C
        • Verstockt B
        • Gils A
        • Noman M
        • Van Kemseke C
        • Macken E
        • et al.
        Long-term clinical effectiveness of ustekinumab in patients with Crohn's disease who failed biologic therapies: a national cohort study.
        J Crohn's Colitis. 2019; 13: 1401-1409
        • Takeda K
        • Kikuchi K
        • Kanazawa Y
        • Yamasaki K
        • Aiba S.
        Ustekinumab treatment for hidradenitis suppurativa.
        J Dermatol. 2019; 46: 1215-1218
        • Hanzel J
        • Ma C
        • Casteele NV
        • Khanna R
        • Jairath V
        • Feagan BG.
        Vedolizumab and extraintestinal manifestations in inflammatory bowel disease.
        Drugs. 2021; 81: 333-347